Shares of Adamas Pharmaceuticals Inc (NASDAQ:ADMS) have earned a consensus recommendation of “Buy” from the twelve analysts that are currently covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and eight have given a buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $42.00.

ADMS has been the subject of several analyst reports. Noble Financial reissued a “buy” rating on shares of Adamas Pharmaceuticals in a research note on Wednesday, August 9th. Cowen set a $45.00 price objective on shares of Adamas Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, August 9th. Mizuho reaffirmed a “buy” rating and set a $48.00 price objective (up previously from $26.00) on shares of Adamas Pharmaceuticals in a research note on Wednesday, September 13th. Needham & Company LLC reaffirmed a “buy” rating and set a $38.00 price objective on shares of Adamas Pharmaceuticals in a research note on Sunday, September 17th. Finally, ValuEngine raised shares of Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, September 1st.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. American International Group Inc. grew its holdings in shares of Adamas Pharmaceuticals by 7.1% during the 1st quarter. American International Group Inc. now owns 10,284 shares of the specialty pharmaceutical company’s stock worth $180,000 after purchasing an additional 682 shares during the period. Alps Advisors Inc. grew its holdings in shares of Adamas Pharmaceuticals by 6.7% during the 2nd quarter. Alps Advisors Inc. now owns 20,182 shares of the specialty pharmaceutical company’s stock worth $353,000 after purchasing an additional 1,272 shares during the period. SG Americas Securities LLC purchased a new stake in shares of Adamas Pharmaceuticals during the 3rd quarter worth about $110,000. Quantbot Technologies LP purchased a new stake in shares of Adamas Pharmaceuticals during the 3rd quarter worth about $119,000. Finally, Geode Capital Management LLC grew its holdings in shares of Adamas Pharmaceuticals by 4.9% during the 1st quarter. Geode Capital Management LLC now owns 125,793 shares of the specialty pharmaceutical company’s stock worth $2,201,000 after purchasing an additional 5,920 shares during the period. 79.45% of the stock is owned by institutional investors.

Shares of Adamas Pharmaceuticals (ADMS) traded down $1.22 during mid-day trading on Thursday, reaching $35.93. 1,632,345 shares of the company traded hands, compared to its average volume of 1,016,909. Adamas Pharmaceuticals has a 12-month low of $13.50 and a 12-month high of $38.22. The company has a debt-to-equity ratio of 0.41, a current ratio of 8.35 and a quick ratio of 8.32.

Adamas Pharmaceuticals (NASDAQ:ADMS) last announced its earnings results on Thursday, November 2nd. The specialty pharmaceutical company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($1.01) by ($0.03). During the same quarter in the previous year, the business earned ($0.66) EPS. The company’s revenue was down 99.3% compared to the same quarter last year. analysts expect that Adamas Pharmaceuticals will post -3.87 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This news story was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/12/03/brokerages-set-adamas-pharmaceuticals-inc-adms-target-price-at-42-00.html.

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Analyst Recommendations for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Stock Ratings for Adamas Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.